Intrinsic and acquired multidrug resistance (MDR) is an important problem in cancer therapy. MDR in human KB carcinoma cells selected for resistance to colchicine, vinblastine, or doxorubicin (former generic name adriamycin) is associated with overexpression of the "MDR] " gene, which encodes P-glycoprotein. We previously have isolated an overlapping set of cDNA clones for the (20).
glycoprotein of Mr 170,000 (P-glycoprotein) (8) (9) (10) ; (v) amplification and overexpression of "MDR]," the gene conferring MDR, or the gene for P-glycoprotein (11) (12) (13) (14) (15) (16) (17) (18) . Transfer of the human, mouse, and hamster MDR] or P-glycoprotein gene sequences has been linked to the transfer of the MDR phenotype (19) (20) (21) . In this work we show that a full-length cloned human MDR] c)NA sequence can confer multidrug resistance in sensitive cells. Similar results using the mouse MDR gene have been recently reported (22) .
MATERIALS AND METHODS
Transfection. DNA transfection of NIH 3T3 cells and KB3-1 cells was performed by a calcium phosphate precipitation method as described (20) .
DNA and RNA Blot Hybridization. DNA was extracted from transfectants (13) and used for Southern blots (23) . Total cellular RNA was isolated from the transfectants (20) and used for RNA blots (23) . The 3.4-kilobase (kb) cDNA probe was labeled with 32P to a specific activity of 1-2 x 109 dpm/,ug by nick translation. Hybridization was done at 42°C in 50% formamide containing 5 x NaCl/Cit (lx = 0.15 M NaCl/ 0.015 M sodium citrate, pH 7), 0.2% bovine serum albumin, 0.2% polyvinylpyrrolidone, 0.2% Ficoll, 0.1% NaDodSO4, 50 mM Tris*HC, and 100 ,ug of salmon sperm DNA per ml, followed by washing with 0.2x NaCl/Cit containing 0.2% NaDodSO4 at 60°C for DNA hybridization and with O.1x NaCl/Cit containing 0.1% NaDodSO4 at 70°C for RNA hybridization at high stringency.
Ribonuclease Protection Assay. Human MDR] mRNA transcribed from the retroviral promoter was detected with a ribonuclease protection assay using a uniformly labeled SP6 antisense RNA probe (785 nucleotides) derived from a 1-kb genomic fragment containing the MDR] transcription initiation site and the first intron of the MDRJ gene cloned in pGEM3 (Promega Biotec, Madison, WI). Total cellular RNA (10 ,ug) was hybridized with 6 x 105 cpm of probe, and ribonuclease digestion was performed as described (24) .
RESULTS
Construction of a Full-Length cDNA for the Human MDR] Gene. Using a genomic MDRJ probe (14) , we isolated an overlapping set of cDNA clones for the MDR] gene from a phage Xgtll cDNA library made from mRNA from the MDR human KB carcinoma mutant line KB-C2.5 (25) . Sequence analysis (26) Fig. 1 . Three inserts from phages 1XHDR5, 10 , and 104 were subcloned into the EcoRI site of a pGEM4 vector.
The insert from XHDR5 was subcloned as two fragments (A and B) after EcoRI digestion. Fragment SA was the fragment 3' to fragment SB. Insert 10, prepared from pMDR10-2, was introduced into pMDR5A-2, which was partially digested with EcoRI. Then the Sst I-HindIII fragment from pMDR10+5A and the HindIII-EcoRI fragment from pMDR104-2 were inserted into the Sst I-EcoRI sites of pGEM2. This step removed the 5'-end EcoRI-Sst I noncoding region from fragment 10. The human MDRI gene that is expressed in colchicine-selected KB cells has two promoters (25) (9) , which was selected in medium containing colchicine at 2.5 ,g/ml. The bottom shows the reconstruction of a full-length cDNA and its introduction into the mammalian expression vector pGV16. Restriction sites: A, Acc I; B, BamHI; E, EcoRI; H, HindIII; P, Pvu II; S, Stu I; T, Sst I; X, Xmn I.
(K.U., M.M.G., and I.P., unpublished results) use mainly the downstream promoter and transcription starts from the Sst I site. Therefore, the 4396-nucleotide insert in pMDR2000, containing a 23-nucleotide poly(A) stretch at its 3' end, is a full-length cDNA for the human MDRJ gene.
The Human MDR] Gene Confers MDR. To test the function of the isolated MDR] gene, the 4.4-kb insert of pMDR2000 was introduced into the eukaryotic expression vector pGV16, a gift of Terry Robins [Frederick Cancer Research Center (27) ] and designated pGMDR (Fig. 1) . The pGV16 vector has the long terminal repeats (LTRs) of Moloney murine leukemia virus (Mo-MuLV) as a promoter just before the cloning sites, and it also contains a G418-resistance gene (neo) under control of the simian virus 40 promoter. The expression plasmid pGMDR was transfected into drug-sensitive NIH 3T3 cells by using a two-step protocol previously described for the transfer of the human genomic MDR] gene into NIH cells, which was designed to enrich for transfected cells and to reduce the background of spontaneous drug-resistant NIH 3T3 cells (20) . Transfected cells were first enriched by selection in medium containing G418 at 0.8 mg/ml (20) ; then pooled G418-resistant cells were selected in medium containing colchicine at 60 ng/ml, which is 3-5 times as high as the LD50 of colchicine for the parental NIH 3T3 cells. Six insert were found to be resistant to colchicine at 60 ng/ml. Therefore, the emergence of colchicine-resistant colonies appeared to result from transfection of the human MDRJ gene. To examine the role of the human MDRJ gene in the MDR phenotype, five colonies were isolated and their levels of cross-resistance to colchicine, vinblastine, and doxorubicin were examined ( Fig. 2 and Table 1 ). All five colonies were cross-resistant to colchicine, vinblastine, and doxorubicin. They showed 6-to 15-fold, 3-to 10-fold, and 1.5-to 3-fold increases in resistance to colchicine, vinblastine, and doxorubicin, respectively, when compared with control NIH 3T3 cells. The pattern of relative resistance was not identical in each cell line. One transfectant was analyzed in greater detail and found to be 4-fold resistant to actinomycin D and 2-fold resistant to puromycin.
To demonstrate the presence of the human MDRI gene in the transfected cells, genomic DNAs were digested with EcoRI and analyzed by Southern hybridization (Fig. 3) . Table 1 ). The 3.4-kb cDNA probe was also used to analyze transcripts in transfectants by RNA hybridization (Fig. 4) Table 2 shows that this construction also produced MDR clones. In these experiments, instead of first selecting for G418 resistance and then screening the surviving cells for resistance to colchicine, vinblastine, or doxorubicin, we directly selected transfected cells with colchicine, vinblastine, or doxorubicin. Colchicine-, vinblastine-, or doxorubicin-resistant colonies could be selected directly with a frequency of about 1 in 1000-5000 ( Table 2 ). The frequency of colchicine-resistant colonies was similar to the frequency of G418-resistant colonies when using 3 ;Lg of pSV2neo DNA or 10 pg of pGV16 DNA with the same transfection protocol. No drug-resistant clones pCO12 (EGFR) 0 0 0 KB3-1 (3 x 105 cells per 10-cm dish) were transfected with 10 ug of DNA; 48 hr after transfection, the cells were split into three dishes and cultured in the presence of colchicine (10 ng/ml), vinblastine (4 ng/ml), or doxorubicin (30 ng/ml). On day 9, the cells were stained and colonies counted.
resulted from transfecting KB cells with pCO1 itself, which contains a functional p21 gene or a similar vector in which a cDNA from the human epidermal growth factor receptor replaced p21 (T. J. Velu, D. R. Lowy, and I.P., unpublished results).
DISCUSSION
These results show that a reconstructed full-length cDNA for the MDRJ gene produces a functional P-glycoprotein. High expression of this MDR] cDNA appears to be sufficient to confer the MDR phenotype. Although we cannot eliminate the possibility of the involvement of some host cell proteins or cofactors in expression of the MDR phenotype, for example in "trapping" the drug and "delivering" it to P-glycoprotein, the limiting step in MDR appears to be the amount of the product of the MDR] gene (P-glycoprotein). Our results also indicate that high copy numbers of the MDRJ gene are not necessary for resistance to low concentrations of drugs. We have previously shown that in MDR cell lines, activation of transcription can precede gene amplification (15) . In clinical situations, a low degree of resistance resulting from MDR] gene activation appears to be sufficient to cause MDR in some human tumors (30) .
Previous studies have indicated that the relative degree of resistance to individual drugs in the MDR phenotype is highly variable (9, 15) . In this work, using a transfected cDNA for the MDR] gene, we also observed considerable variation in relative drug-resistances (compare colchicine/vinblastine relative resistances in Table 1 ). These results suggest that host factors, such as expression of other proteins and posttranslational modification of the P-glycoprotein, may play a role in modulating the MDR phenotype.
In the two-step protocol, using the Mo-MuLV LTR containing vector pGV16, the frequency of MDR colonies among G418-selected transfectants was approximately 6 x 10-4 to 1 X lo-,, to give an overall frequency of MDR transfectants of between 6 x 1O-7 and 1 x 10-6. This is lower than the frequency of 2 x 10-4 observed by Gros et al. (22) , who selected directly for doxorubicin-resistance with a cloned mouse mdr cDNA. It seemed likely that the relatively low transfection efficiency was related to inefficient expression of the Mo-MuLV LTR MDRJ construction, so we prepared another construction using a Ha-MSV LTR and found that we could directly select MDR colonies at a frequency of approximately lo-3. These results suggest that when introduced into bone marrow, the human MDR] cDNA clone might be useful as a positive selectable marker for the introduction of other genes in gene therapy or to make human bone marrow cells resistant to drugs used in chemotherapy so that cancers can be treated more aggressively (30) .
As already noted, sequence analysis of the human (26), mouse (31) , and hamster (32) mdr gene products indicates that they have features consistent with the predicted function of P-glycoprotein as an energy-dependent efflux pump responsible for decreased drug accumulation in MDR cells. The functional full-length human cDNA under the control of an active retroviral promoter constructed for this work will facilitate the biochemical study of this human drug efflux pump and may be useful for introduction of the human MDR gene into bone marrow and other tissues.
